Pherecydes Pharma presented at the ECCMID congress an analytical performance protocol demonstrating

NANTES, France--(BUSINESS WIRE)--Regulatory News:Pherecydes Pharma (FR0011651694 - ALPHE) (Paris:ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections (the “Company”), presented part of its analytical performance plan adapted to its Phagogr...

Related Keywords

France ,Paris ,France General ,Denmark ,French ,Dusan Oresansky Nicolas Fossiez ,Pherecydes Pharma ,Arthur Rouill ,European Congress ,Regulatory News ,Clinical Microbiology ,Infectious Diseases ,Rafael Gomes Von Borowski ,Development Manager ,Antimicrobial Susceptibility Testing ,Nicolas Fossiez ,